Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]-VAD044
NL-OMON60023Phase 1Completed
- Sponsor
- Vaderis Therapeutics AG
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of engasertib in vascular malformation, sponsored by Vaderis Therapeutics AG. Started Dec 2024; status: completed.
02
Drugs
engasertib
03
Conditions
vascular malformation
Beyond the preview
Go deeper on NL-OMON60023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60023.